Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia

R. Benecke, W. H. Jost, Petr Kaňovský et al. · Neurology · 2005 · 270 citations

New Botulinum Toxin, Nt 201, Cervical Dystonia +2

Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Danièle Ranoux, C. Gury, J Fondarai et al. · PubMed · 2002 · 267 citations · Full text

Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm

P. Roggenkämper, Wolfgang H. Jost, Katalin Bihari et al. · Journal of Neural Transmission · 2005 · 244 citations

Microbial Toxin, Toxinology, Allergy +2

Therapeutic botulinum type a toxin: Factors affecting potency

Kay McLellan, Rose E. Gaines Das, Theresa Ekong et al. · Toxicon · 1996 · 93 citations

Toxinology, Medicine, Toxicology +3

Routine use of Xeomin^® in patients previously treated with Botox^®: long term results

Dirk Dressler · European Journal of Neurology · 2009 · 82 citations